Our calculations revealed that the DHX34 low group exhibited lower TIDE scores in KIRP, LGG, LIHC, and SKCM, indicating that lower DHX34 expression predicts a more favorable ICI treatment response in these cancers (Fig. 12A-D). The gene discussed is DHX34; the disease is cancer.